Docbot’s artificial intelligence platform can be trained to predict levels of ulcerative colitis severity after reviewing full-length endoscopy videos, AiThority reported Nov. 6. Researchers studied ...

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 Data from the ...

For patients who experience endoscopic remission of ulcerative colitis (UC), signs of active disease on histology did not affect their risk of clinical relapse, according to a large prospective study ...

In patients with ulcerative colitis who had endoscopic healing, achieving transmural healing was associated with longer relapse-free survival. Women and those who had received multiple advanced ...

The diagnosis of ulcerative colitis (UC) is based on clinical evaluation and medical history and confirmed through laboratory, radiologic, endoscopic and histologic findings. Before making the ...

Please provide your email address to receive an email when new articles are posted on . Etrasimod — an oral, selective sphingosine-1-phosphate receptor modulator — was effective in inducing endoscopic ...

Assessments of patients with ulcerative colitis (UC), which is a type of inflammatory bowel disease, are usually conducted via endoscopy and histology. But now, researchers from Japan have developed a ...

Floris de Voogd, MD; Elsa A. van Wassenaer, MD; Aart Mookhoek, MD, PhD; Steven Bots, MD; Sara van Gennep, MD; Mark Löwenberg, MD, PhD; Geert R. D’Haens, MD, PhD ...

The American Gastroenterology Association unveiled new guidelines for patients with ulcerative colitis, according to HCPLive. 1. Joseph Feuerstein, MD, and his gastroenterology team at Beth Israel ...

While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in ...

PARIS--(BUSINESS WIRE)--Regulatory News: ABIVAX SA (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments ...

Furthermore, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, TREMFYA® demonstrated clinically meaningful results across all endpoints in both biologic ...